For film-coated immediate-release tablets containing 2.5 mg, 5 mg, 10 mg, or 20 mg of tadalafil per unit, the particle-size distribution of the API is the first critical control point. Tadalafil is frequently assigned to BCS Class II or IV depending on the buffer system because its equilibrium solubility remains below 5 µg/mL in pH 6.8 phosphate buffer and rises only marginally in 0.1 N HCl at 37 °C. Unmilled API with a d90 above 40 µm is associated with dissolution Q-values at 30 min below 75% even when tablet hardness is held at 60–90 N and disintegration time remains inside the 15 min limit of USP <701>. Spiral jet milling with compressed nitrogen at 6–10 bar, grinding nozzle pressure of 4–6 bar, and classifier speed configured for a feed rate of 15–30 kg/h is therefore used to reduce primary particles to a d90 of 5–15 µm as measured by laser diffraction under USP <429>. Milled material is discharged through a cyclone with a surface temperature not exceeding 35 °C; hotter discharge temperatures have been associated with agglomeration and electrostatic charge accumulation on stainless steel contact surfaces. The micronized powder is screened through a 500 µm sieve and blended with mannitol, microcrystalline cellulose, croscarmellose sodium, and colloidal silicon dioxide. The tadalafil fraction in the core typically does not exceed 12% w/w because higher drug loading reduces blend flowability and increases the segregation tendency of the low-density API across hopper-induced shear. Magnesium stearate is added at 0.5–1.0% w/w in the final blending step, and total lubrication time is held below 5 min at 15–25 rpm to avoid surface coverage that delays drug release.

Wet granulation becomes mandatory when the tablet press feed frame is operated above 30 rpm because direct-compression blends of milled tadalafil have shown die-fill weight variability above 3.5% RSD at press speeds beyond this threshold. A high-shear granulator equipped with an impeller at 250–350 rpm and a chopper at 1,500–2,500 rpm is used with an aqueous hypromellose binder solution at 3–5% w/w solids, added to a final granulation moisture of 8–12% w/w. The wet mass is passed through a 1.0 mm screen and dried in a fluid-bed dryer with inlet air at 50–60 °C until the loss on drying reaches 1.0–2.0% w/w; overdried granules generate fines that segregate during transfer, while residual moisture above 2.5% w/w increases sticking on tablet tooling. Compression on a rotary press runs with precompression at 5–8 kN and main compression at 12–25 kN, producing tablets with hardness 60–100 N and friability below 1.0% per USP <1216>. Weight variation is monitored against USP <905>; tablets outside the ±5% individual weight window are rejected by an automatic checkweigher. Aqueous PVA-based film coating is applied to 3.0–4.0% w/w weight gain in a perforated pan at inlet air temperature 60–70 °C, product bed temperature 38–42 °C, pan speed 6–12 rpm, and spray rate 8–15 g/min per kg of core bed. Processing at product-bed temperatures above 42 °C has produced edge chipping and logo bridging on embossed tooling, while a bed temperature below 36 °C delays film coalescence and increases water uptake by the core. Finished tablets packaged in PVC/PVDC/aluminium blisters are placed on ICH Q1A(R2) stability protocols with accelerated conditions at 40 °C / 75% RH; if cold-form foil is not used, the water vapor transmission rate of the blister must be verified below 0.5 g/m²/day by ASTM F1249.

How Does Capsule Filling Expose Tadalafil’s Static and Flow Limitations?

Capsule filling of tadalafil blends on a tamping-pin machine reveals that a tadalafil–lactose monohydrate blend containing 0.5% w/w magnesium stearate loses content uniformity when the blend is mixed beyond 5–8 min; over-lubrication reduces the tensile strength of slugs formed inside the tamping pins and shifts dissolution at 15 min below the release threshold. The low bulk density of micronized tadalafil, typically 0.25–0.40 g/cm³, creates a powder bed that collapses unevenly under dosator compression, producing fill weight RSD values above 3.5% at machine speeds above 50,000 capsules/h. Direct filling of unmilled cohesive powder is therefore avoided; roller compaction or slugging is used to increase bulk density to 0.55–0.70 g/cm³ before filling. Roller-compacted granules are milled through a 800 µm screen, and the fraction retained on a 200 µm screen is kept above 60% w/w to minimize segregation. For a 20 mg tadalafil strength, a size 3 hard HPMC or gelatin capsule with fill weight 120–180 mg is typical; size 2 capsules may be required when the formulation includes disintegrant and lactose beyond 80% w/w. HPMC shell moisture is maintained at 3–7% w/w; equilibrium relative humidity below 35% causes shell splitting during high-speed filling, while feed-frame humidity above 60% RH increases powder adhesion to the dosing disk and produces capsule weight drift. Gelatin shells present a crosslinking risk if residual aldehydes or peroxide impurities from wet granulation are not removed; the dissolution test under USP <711> may then require a pepsin digestion stage in 0.1 N HCl at 37 °C to distinguish pellicle formation from true formulation failure. Capsule content uniformity is assessed by USP <905>, and moisture is monitored by loss on drying with a limit of 2.0–4.0% w/w. Automated checkweighing with a ±3% rejection limit is applied after filling, and metal detection follows at the end of the line.

Capsule dissolution variability often originates from powder bed stratification rather than API solubility. Because tadalafil particles smaller than 10 µm carry high electrostatic charge, they adhere to the gelatin or HPMC inner wall and can delay release when the capsule does not open cleanly. Preconditioning capsules with a static eliminator bar and maintaining filling room relative humidity at 40–50% reduces surface charge and improves API recovery in the dissolution vessel. Dissolution testing uses 900 mL of 0.5% SLS in 0.1 N HCl at 37 °C with USP Apparatus II at 50 rpm, matching the immediate-release tablet method; if the capsule shell delays rupturing beyond 15 min, the Q value at 30 min is no longer a reliable release indicator and the method must be revised with an enzyme stage or a two-point specification. Stability studies under ICH Q1A(R2) for hard capsules are run at 40 °C / 75% RH, but packaging in PVC/PVDC/aluminium blister is preferred because HPMC shells gain moisture above 60% RH and become tacky, while gelatin shells can become brittle below 35% RH in cold storage. The moisture vapor transmission rate of the blister film should be verified below 0.5 g/m²/day by ASTM F1249.

Orally disintegrating tablet development compresses tadalafil with co-processed mannitol, crospovidone, and sodium starch glycolate; the critical operating window is set by the conflict between mechanical strength and disintegration time. Direct compression on a rotary press with multi-tip tooling at press speed 20–40 rpm and precompression 3–5 kN produces ODT hardness of 20–35 N; increasing main compression above 10 kN collapses the mannitol pore network and pushes disintegration beyond 60 s in 900 mL water at 37 °C under USP <701>. Tadalafil’s low aqueous solubility requires the superdisintegrant to function as a wicking channel as well as a swellable matrix disruptor; crospovidone at 5–10% w/w is combined with sodium starch glycolate at 2–5% w/w because the two mechanisms differ in wetting rate and gel strength. The tadalafil fraction is kept below 8% w/w and the API d90 is tightened to 5–10 µm to prevent gritty mouthfeel and to preserve content uniformity during the high-dilution blending step. Compression of the ODT blend at ambient relative humidity above 45% causes ejection sticking; tooling is therefore fitted with a nanohydroxyapatite or chrome-composite punch coating, and the press is isolated with dehumidified air at 20–25% RH. Tablets are packaged in peelable aluminium pouches with desiccant because the mannitol core absorbs moisture and loses tensile strength above 40% RH. In-process control includes tablet weight variation per USP <905>, disintegration testing at 37 °C, and residual water content by Karl Fischer titration with a release limit below 1.0% w/w. If freeze-dried ODT technology is used instead of direct compression, the tadalafil suspension must be filled into preformed blister pockets with a dose-cavity volume margin of ±5% to avoid cracking of the lyophilized matrix; published data for this specific configuration is limited.

Granule Risk Mapping for Sachet and Oral Suspension Processing

When single-dose sachets are produced, fluid-bed top-spray granulation of tadalafil begins with the API suspended in an aqueous binder solution because the drug substance does not dissolve at neutral pH. The suspension is sprayed at 10–20 g/min onto a mannitol–microcrystalline cellulose bed in a fluid-bed granulator with inlet air temperature 55–65 °C, product temperature 30–35 °C, and atomization air pressure 1.5–2.5 bar. The granulation endpoint is reached when the product moisture reaches 8–12% w/w; after drying to loss on drying 1.0–1.5% w/w, the granules are screened through 710 µm and 150 µm sieves. Fines below 150 µm are limited to <15% w/w because their high surface charge causes dusting and fill-weight drift on auger-type sachet machines at speeds above 60 sachets/min. Each sachet is filled with 250–500 mg of granules to deliver 5 mg or 20 mg tadalafil; fill weight variation is controlled to ±5% by periodic checkweighing, and content uniformity follows USP <905> for the reconstituted dose. The sachet film is a PET/aluminium/LDPE laminate; the moisture vapor transmission rate must remain below 0.1 g/m²/day at 38 °C/90% RH when tested under ASTM F1249, because tadalafil granules packaged in less protective film have shown moisture absorption above 2.0% w/w at 6 months in Zone IVb conditions. Reconstitution in 30–60 mL of water at 25 °C produces a suspension with dose recovery above 95% if the granules contain sodium lauryl sulfate at 0.5–1.0% w/w; without the wetting agent, tadalafil particles float on the liquid surface and stick to the dosing cup, causing a measured dose loss above 10%. The reconstituted suspension should be administered immediately because tadalafil settles at a rate that increases with particle size; granules with d90 above 25 µm settle within 2–3 min and require shaking. Stability of the granule line is run under ICH Q1A(R2) accelerated conditions at 40 °C / 75% RH for 6 months, with related substances controlled by HPLC per USP <621> and residual solvents per ICH Q3C.

Higher binder viscosity from hypromellose solutions above 5% w/w produces harder granules with friability below 1.0%, but the same granules release tadalafil more slowly because the polymer matrix retards wetting. For granule blends intended for immediate release after reconstitution, the hypromellose viscosity grade is kept at 3–6 mPa·s as a 2% w/w aqueous solution, and the binder level is capped at 3% w/w of the dry granule mass. Above these limits, dissolution Q at 30 min drops below 75% even though bulk granule flow and sachet fill consistency improve. Wet granulation using water only is avoided on production scale because the tadalafil suspension sediment observed in the holding tank requires continuous recirculation at 50–100 rpm to maintain dose uniformity across the spray interval; without recirculation, the first sachets of a batch show up to 20% label under-potency while the final sachets show corresponding over-potency. Holding tank residence time is limited to <4 h at 15–25 °C to minimize microbial growth in the non-sterile granulation line, and the tank is cleaned with hot purified water at 70–80 °C followed by ethanol wipe-down.

When Sterile Filtration Demands pH Control: Injectable Tadalafil Processing

Published data for a commercial injectable tadalafil presentation is limited, so the following process limits are derived from preformulation studies of the API in sterile liquid systems rather than a compendial monograph. Tadalafil has an intrinsic aqueous solubility of approximately 2 µg/mL at 25 °C in unbuffered water; this requires a solubility-enhancing strategy before sterile filtration can be considered. Protonation of the weakly basic molecule increases solubility only below pH 2.0, but acidic conditions accelerate degradation and attack stainless steel transfer lines; electropolished 316L stainless steel with surface roughness Ra <0.4 µm is specified for the solution hold tank and filter housing. Sulfobutylether-β-cyclodextrin at 10–30% w/v is evaluated as a complexing agent because it shifts the apparent solubility into the 1–5 mg/mL range at pH 3.0–4.0 and avoids the hydrolysis risk of strongly acidic co-solvent systems. A co-solvent approach using PEG 300 and propylene glycol at 30–50% v/v total organic phase is less favored for intravenous administration because the high osmolality must then be corrected with water or a tonicity agent to remain within the 280–320 mOsm/kg range of USP <785>. Sterile filtration through a 0.22 µm PVDF filter is preferred over nylon and PES membrane alternatives; membrane-binding studies screen the filter at tadalafil concentrations of 0.1–1.0 mg/mL because drug adsorption to the membrane at low concentrations can reduce potency by more than 10% if the first filtrate volume is not discarded. Filter integrity is verified by bubble point or forward flow per ASTM F838 before and after filtration. Terminal sterilization by autoclaving at 121 °C for 15 min is evaluated only after forced degradation studies show ≤0.5% total degradation products at pH 3.0–5.0; if the cyclodextrin complex dissociates under heat, subvisible particulates above the 10 µm threshold increase and the batch fails USP <788> particle count limits. Aseptic processing is therefore the default route for heat-labile formulations, with sterility assurance per USP <71> and bacterial endotoxin limits per USP <85>. Visible particulate inspection under USP <790> is performed on 100% of filled units; automated inspection detects glass flake shedding from the fill needle when the rubber stopper insertion force exceeds 40 N. The operational boundary is strict: pH excursions above 5.0 during holding precipitate the API, and holding times in stainless steel vessels at pH below 2.5 must be kept below 8 h at 2–8 °C to stay within impurity limits.

Fixed Dose Combinations Require Segregated Granulation Lines

In jurisdictions where a tadalafil / tamsulosin hydrochloride fixed-dose combination is approved, the formulation strategy must separate the immediate-release tadalafil phase from the controlled-release tamsulosin component. Tamsulosin hydrochloride is a low-dose 0.4 mg alpha-blocker with a narrow therapeutic window, and a rapid gastric bolus can increase orthostatic hypotension events; the tamsulosin fraction is therefore coated onto sugar spheres with an ethylcellulose or methacrylic acid copolymer diffusion membrane tuned to release over 6–8 h. The tadalafil fraction is granulated separately on a dedicated line because residual tamsulosin powder at the 0.1% w/w level can cross-contaminate subsequent non-combination batches; clean verification uses swab and rinse sampling with an HPLC limit below the health-based exposure threshold derived from a permitted daily exposure assessment. Tadalafil granules are prepared by high-shear granulation with mannitol and croscarmellose sodium, dried to loss on drying 1.0–2.0% w/w, and milled through an 800 µm screen. The two components are filled into hard capsules or compressed into a bilayer tablet using separate hoppers and segregated vacuum transfer lines. In bilayer compression, the first layer is compressed at 8–12 kN to a hardness of 30–45 N, then the second layer is applied with a total compression force of 15–25 kN; if the first layer hardness exceeds 50 N, interlayer adhesion fails and the tablet splits at the interface during coating and packaging. The tadalafil layer releases in 0.5% SLS in 0.1 N HCl under USP <711> Apparatus II at 50 rpm; the tamsulosin layer requires a two-stage dissolution test combining acidic and pH 6.8 phosphate buffer conditions because the diffusion coating is pH-sensitive. Content uniformity is tested per USP <905> for the tadalafil label claim and per a validated HPLC method for the 0.4 mg tamsulosin fraction. The fixed-dose line is operated at 20–25 °C and 35–45% RH because tamsulosin-coated pellets become tacky above 45% RH, causing pellet agglomeration and dose-dumping during capsule filling. Stability protocols follow ICH Q1A(R2) with 6-month accelerated storage at 40 °C / 75% RH; tadalafil degradation products are controlled by USP <621> HPLC, and the dissolution profile of the tamsulosin layer must remain within f2 similarity limits when compared with the reference controlled-release component. The production bottleneck is the drying capacity of the tamsulosin pellet line: coating a batch of 0.4 mg pellets to 6–8 h release extends batch cycle time by 10–14 h compared with a monolayer tablet, so campaign scheduling is based on coating drum occupancy rather than compression capacity.

An incompatibility risk in the combination line is the interaction between croscarmellose sodium and the cationic tamsulosin coating; the anionic disintegrant can adsorb tamsulosin from solution during dissolution testing and produce a falsely low recovery of the alpha-blocker. This has been observed when the two components are blended into a single powder matrix rather than kept segregated. In pilot trials, a mixed blend containing 5% w/w croscarmellose sodium produced tamsulosin recovery below 90% at 15 min, while the bilayer configuration recovered above 95%. The official control strategy therefore forbids the use of anionic superdisintegrants in the tamsulosin matrix and uses a non-ionic disintegrant such as crospovidone in the tadalafil layer only. Process analytical technology using near-infrared probes at the feed frame monitors tadalafil layer potency at 10 s intervals; the probe tolerance is set at ±5% label claim because the low-dose tadalafil signal overlaps with mannitol hydroxyl bands. Published data for this specific combination configuration is limited to the stability and dissolution studies filed with the relevant marketing authorization; no additional in vivo performance data is assumed.